What Are Possible Contraindications for NSAIDs?

Anlixin is a drug, this product is a non-steroidal anti-inflammatory drug (NSAID), suitable for the treatment of rheumatoid arthritis, pain osteoarthritis (arthropathy, degenerative osteoarthritis).

An Liqing

Anlixin is a drug, this product is a non-steroidal anti-inflammatory drug (NSAID), suitable for the treatment of rheumatoid arthritis, pain osteoarthritis (arthropathy, degenerative osteoarthritis).

Drug Name

An Liqing

Main indications

Non-steroidal anti-inflammatory drugs

[Chemical composition] The main ingredient of this product is meloxicam, and its chemical name is 4-hydroxy-2-methyl-N- (5-methyl-2-thiazolyl) -2H-1,2-benzothiazine Azine-3-carboxamide-1,1, -dioxide.

This product is an enol non-steroidal anti-inflammatory drug (NSAID), which has strong anti-inflammatory, analgesic and antipyretic effects. It can inhibit the synthesis of prostaglandins and selectively inhibit cyclooxygenase-2 (COX 2), which is more safe than other NSAIDs.

1 Large doses of other NSAIDs include salicylate: the simultaneous use of more than one NSAID may increase the likelihood of gastrointestinal ulcers and bleeding through synergistic effects.

2 Oral anticoagulants, ampicillin, and the systematic use of heparin and thrombolytic agents can increase the possibility of bleeding. If the combination is unavoidable, the effects of anticoagulants must be closely monitored.

3 Lithium: NSAID has been reported to increase the plasma concentration of lithium. It is recommended to monitor plasma lithium levels when starting, adjusting and discontinuing this product. 4 Methotrexate: Similar to other NSAIDs, meloxicam increases the blood toxicity of methotrexate. In this case, it is recommended to strictly monitor the number of blood cells. <BR dd>

According to foreign research data, the incidence of side effects of oral administration of this product is as follows:

1 gastrointestinal:

More than 1%: indigestion, nausea, vomiting, abdominal pain, constipation, flatulence, diarrhea.

Frequency between 0.1% and 1%: transient abnormalities in liver function (such as elevated aminotransferase or bilirubin).

Esophagitis, stomach, duodenal ulcers, latent or visible gastrointestinal bleeding.

Less than 0.1%: gastrointestinal perforation, colitis.

2 Blood:

More than 1%: Anemia.

Frequencies between 0.1% and 1%: Imbalanced blood cell counts, including white blood cell counts, leukopenia and thrombocytopenia,

People who are allergic to this product, those with active peptic ulcer, those with severe liver dysfunction, those with non-dialysis and severe kidney dysfunction, who have symptoms of asthma, nasal polyps, angioedema or urticaria after using acetylsalicylic acid or other NSAID Patients, children under 15 years old, adolescents, and pregnant and lactating women are contraindicated.

Rheumatoid arthritis: 15 mg per day. Depending on the response after treatment, the dose can be reduced to 7.5 mg / day.

Osteoarthritis: 7.5 mg / day, if required, the dose can be increased to 15 mg / day.

For patients who are likely to have an increased adverse reaction: Start of treatment at a dose of 7.5 mg / day.

Patients with severe renal failure on dialysis: The dose should not exceed 7.5 mg / day.

The appropriate dose for children has not been determined and is currently restricted to adults.

The maximum recommended daily dose is 15 mg, swallowed with water or liquid. [Storage method] Shade and sealed. The validity period is tentatively set at one and a half years. [Product Specifications] 7.5mg

As with other NSAIDs, patients who have a history of upper gastrointestinal tract and are using anticoagulants should pay attention to this product. If peptic ulcer or gastrointestinal bleeding occurs, stop using this product.

Patients with adverse reactions to mucous membranes and skin should pay special attention and consider stopping using this product.

NSAID can inhibit the synthesis of renoprost which plays a supporting role in maintaining renal perfusion. Therefore, in patients with reduced renal blood flow and blood volume, the use of NSAID may promote significant renal decompensation. Function usually returns to pre-medication levels. These reactions are most likely to occur in the following patients: dehydrated patients, patients with congestive heart failure, patients with cirrhosis, people with kidney disease, and patients with significant kidney disease. ^[1]